Tag Archives: Biotime

Technology

ESI BIO – A Division of BioTime, Inc. Announces New UK Distribution Agreement with 2B

Leave a comment

ESI BIO,the stem cell products division of BioTime Inc.,announces that its cGMP and research grade stem cell lines,reagents and cell matrix products will now be available in the UK and Ireland through 2BScientific Ltd.

Alameda, CA, January 15,2015 – ESI BIO,the stem cell products division of BioTime Inc.,announces that its cGMP and research grade stem cell lines,reagents and cell matrix products will now be available in the UK and Ireland through 2BScientific Ltd.

ESI BIO’s (esibio.com) research products are used by stem cell researchers around the world and include clinical and research grade human embryonic stem cells from ES Cell International (ESI) and HyStem® hyaluronan-based hydrogel extracellular matrices. ESI BIO also provides unique PureStem® Embryonic Progenitors, antibodies and small molecules for stem cell differentiation and reprogramming.

Jeffrey Janus, CEO at ESI BIO commented, “We are pleased to hear that 2BScientific would like to be our distributor in the UK market and we expect that we can build a strong partnership in the future.” James Bernard, CEO of 2BScientific added, “2BScientific is excited to have signed a distribution agreement with ESI BIO to sell all of their stem cell products and services in the United Kingdom and Ireland. We are excited to offer their cell lines and supporting products for stem cell researchers.”

About ESI BIO
ESI BIO – A Division of BioTime, Inc., is a unique research reagent organization which markets and distributes stem cell related research products provided by BioTime and its subsidiary companies. Many of these products can be provided as a research grade or clinical grade, including ES Cell International’s human embryonic stem cell lines and HyStem® hyaluronan-based hydrogels produced under conditions designed to be compliant with principles of current Good Manufacturing Practices (cGMP), making them suitable for use in clinical research and regenerative medicine. ESI BIO’s portfolio includes PureStem® human embryonic progenitors, antibodies, and small molecules for stem cell differentiation and reprogramming. ESI BIO’s mission is to develop innovative research products that help translate scientific discoveries to the clinic. ESI BIO facilities are located in La Jolla and Alameda, California, with a third location in Singapore. Learn more at www.esibio.com

About 2B Scientific
2B Scientific is a specialist distributor of immunological reagents to the UK life science market. 2B Scientific takes a novel approach to life science reagents distribution and provides a wide range of products including antibodies, PCR and flow cytometry reagents, apoptosis assays, proteins and life science consumables. Learn more at www.2BScientific.com

Contact:
Dr. Farjad Ahmed
2B Scientific Ltd
Cherwell Innovation Centre
77 Heyford Park
Upper Heyford
OXON OX255HD
+44 (0)1869 238033
info@2BScientific.com
http://www.2BScientific.com

Technology

ESI BIO (BioTime) Announces New UK Distribution Agreement with 2BScientific Ltd

Leave a comment

ESI BIO’s research products are currently used by stem cell researchers around the world and will now be available exclusively in the UK and Ireland through 2BScientific Ltd.

Alameda, CA, December 09, 2014 – ESI BIO – A Division of BioTime, Inc. specializes in the production of high quality hydrogels, progenitor cells, human embryonic stem cells, and other key tools for stem cell researchers.

Jeffrey Janus, CEO at ESI BIO commented, “We are pleased to hear that 2BScientific would like to be our distributor in the UK market and we expect that we can build a strong partnership in future.” James Bernard, CEO of 2BScientific added, “2BScientific is excited to have signed a distribution agreement with ESI BIO to sell all of their stem cell products and services in the United Kingdom and Ireland. We are excited to offer their cell lines and supporting products for stem cell researchers.”

About ESI BIO:
ESI BIO – A Division of BioTime, Inc. (“ESI Cell International Pte Ltd.”) is a unique research reagent organization which markets and distributes human embryonic stem cell lines under conditions designed to be compliant with principles of current Good Manufacturing Practices (cGMP), making them suitable for use in clinical research and regenerative medicine. ESI BIO’s portfolio includes PureStem® human embryonic progenitors, HyStem® hyaluronan-based hydrogels, antibodies, and small molecules for stem cell differentiation and reprogramming.

ESI BIO’s mission is to develop innovative research products that help translate scientific discoveries to the clinic. ESI BIO facilities are located in La Jolla and Alameda, California, with a third location in Singapore.

Learn more at www.esibio.com

About 2B Scientific:
2B Scientific is a specialist distributor of immunological reagents to the UK life science market. 2B Scientific takes a novel approach to life science reagents distribution and provides a wide range of products including antibodies, PCR and flow cytometry reagents, apoptosis assays, proteins and life science consumables.

Learn more at www.2BScientific.com

Contact:
Georgi Manov
2BScientific Ltd
77 Heyford Park
Upper Heyford OX25 5HD
United Kingdom
+44 1869 238033
info@2BScientific.com
http://www.2bscientific.com

Biotech, Financial, Healthcare, Pharmaceuticals, Science

Investor Stem Cell Launches Online Discussion Community Dedicated To Stem Cell Investors

Leave a comment

APR 29, 2011 /RTPR/ — Investor Stem Cell (http://www.investorstemcell.com) is dedicated to bringing investors and stakeholders together in thoughtful discussion to educate and publicize the incredible medical advancements taking place in the regenerative medicine sector. Scientists are using stem cells both (hESC) and (iPSC) in hopes of easing the suffering of hundreds of millions of people world wide.

Our society is on the verge of a quantum leap moment in time thanks to regenerative medicine.

Regenerative medicine and Stem Cell research:

Utter those words at your next dinner party or casual gathering of friends and family. You will receive a concoction of half-truth’s and out right fallacy responses. Stem Cell research conjures images of futuristic Star–Trek like preservation chambers, human looking ears protruding oddly from the backs of mice, or worse yet an image of a late term fetus. Nothing could be farther from the truth when entering the reality of Regenerative medicine.

Never before has this area of research been more exciting and promising than right now. There is a medical revolution brewing, and like any revolution, there are those who want to suppress this uprising for continued personal and ideological gains. If we were to take all the major advances in the past 500 years of human medical history and multiply its effect by 10 fold it still would not compare to the paradigm shift in health care delivery that the world may witness in this decade using stem cells. Imagine that an $800,000 heart transplant is no longer needed and that instead the same money spent on one patient can now be stretched out to treat 20 patients who are needing a heart transplant. Is this what Regenerative medicine has in the offing? Only time will tell. Our healthcare system could very well be on the verge of a quantum leap moment thanks to regenerative medicine.

The Food and Drug Administration (FDA) authorized 3 trials using human embryonic stem cells (hESC) in late 2010. Validation of hESC research efforts and the culmination of billions spent on research are coming to fruition. FDA validation for the treatments of spinal cord injury and age related macular degeneration is expected in 2011. It may be the shot heard around the world event sometime in late Q-4 2011 for the Regenerative medicine sector.

Find out more at http://www.investorstemcell.com, where investing is much more than charts and numbers.

Investor Stem Cell offers dedicated forums to the following Stem Cell Companies.
Investor Stem Cell is free to all members and employs the state of the art discussion web based software to maximize the experience of its members and the user experience. Get involved now and start separating fact from fiction in Regeneration medicine.

Investor Stem Cell provides Forums for the below Stem Cell Companies.

Advanced Cell Technology (OTC:ACTC) Geron Corporation (NASDAQ:GERN)

Cord Blood America (Public, OTC:CBAI) BioTime (AMEX:BTX)

Aastrom Biosciences (NASDAQ:ASTM) Athersys Inc. (NASDAQ:ATHX)

International Stem Cell Corporation (OTC:ISCO) MultiCell (OTC:MCET)

StemCells, Inc. (NASDAQ:STEM) Thermogenesis (NASDAQ:KOOL)

Bioheart Inc. (OTC:BHRT) RTI Biologics (NASDAQ:RTIX)

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Bio-Matrix Scientific Group (PINK:BMSN)

Neuralstem (AMEX:NBS) Opexa Therapeutics (NASDAQ:OPXA)

Stem Cell Authority (PINK:SCLL) Brainstorm Cell Therapeutics (OTC:BCLI)

Stem Cell Therapeuitics (CVE:SSS) Cyro-Cell International (OTC:CCEL)

CellCyte Genetics(OTC:CCYG) Stem Cell Innovations (PINK:SCLL)

BioMimetic Therapeutics (NASDAQ:BMTI) Mesoblast (ASX:MSB)

Cytori Therapeutics (NASDAQ:CYTX) SANUWAVE Health, Inc. (OTC:SNWV)

Disclosure: By being a visitor and or member of Investor Stem Cell you agree to adhere to the Terms of Service at all times & pay strict attention to (TOS) Stem Cell Media LLC – http://www.investorstemcell.com is not paid by any 3rd party now or in the future to promote “any” companies for credibility and ethical reasons. Investors Stem Cell is not a financial advisory service. Consult your financial advisor at all times before making an investment. Our society is on the verge of a quantum leap moment in time thanks to regenerative medicine.

Contact Details: www.investorstemcell.com
email = icell@investorstemcell.com

###